3 months ago
31
Erin Kennedy, The Motley Fool
Mon, July 6, 2026 astatine 6:55 AM CDT 5 min read
Investing successful biotechnology requires a equilibrium betwixt groundbreaking technological innovation and the realities of objective development. Choosing betwixt CRISPR Therapeutics (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) involves comparing established gene-editing enactment against monolithic maturation imaginable successful metabolic medicine.
CRISPR Therapeutics is simply a person successful cistron editing, precocious achieving its archetypal merchandise support for uncommon humor disorders. Viking Therapeutics focuses connected metabolic and endocrine disorders, targeting the booming marketplace for weight-loss treatments. While some companies run successful high-growth areas, their fiscal stages and objective risks connection chiseled paths for mundane investors.
The lawsuit for CRISPR Therapeutics
CRISPR Therapeutics focuses connected processing gene-based medicines utilizing its proprietary CRISPR/Cas9 platform. The institution develops gene-based medicines, a transformative portion of healthcare stocks. It presently relies connected a strategical concern with Vertex Pharmaceuticals (NASDAQ:VRTX) for the commercialization of CASGEVY, a attraction for sickle compartment disease. Customer attraction similar this adds a furniture of hazard to the concern since 1 spouse controls astir planetary operations.
In fiscal 2025, gross was astir $3.5 million, a alteration of astir 90% compared to the anterior year. The institution reported a nett nonaccomplishment of astir $581.6 cardinal during this period. This show reflects the volatile quality of biotech revenue, which often depends connected one-time milestone payments from collaboration partners alternatively than accordant merchandise sales.
As of CRISPR's December 2025 equilibrium sheet, the existent ratio stands astatine astir 13.3. The existent ratio measures the quality of a concern to screen its short-term obligations with assets it tin person to currency quickly. The debt-to-equity ratio is astir 0.2, showing that full indebtedness is debased comparative to shareholder equity. Free currency travel for fiscal 2025 was astir antagonistic $345.9 million.
The lawsuit for Viking Therapeutics
Viking Therapeutics is simply a clinical-stage institution processing therapies for metabolic and endocrine disorders, including obesity and lipid conditions. The institution operates nether a Master License Agreement with Ligand Pharmaceuticals (NASDAQ:LGND), which provides the rights to its astir promising cause candidates. Viking presently lacks its ain manufacturing infrastructure and relies connected 3rd parties similar CordenPharma for objective cause supplies.
In fiscal 2025, the institution reported nary revenue, arsenic it presently has nary products approved for commercialized sale. Viking recorded a nett nonaccomplishment of astir $359.6 million. This nonaccomplishment widened from erstwhile years arsenic the institution invested much heavy successful its objective pipeline to beforehand its obesity and metabolic candidates.
English (CA) · 
English (US) · 
Spanish (MX) ·